For context, it should be emphasized that other gene-independent, neuroprotective strategies for treatment of patients with IRDs are under study, including rod-derived cone viability factor (RdCVF) (57), N-acetyl cysteine (NAC) (57, 58), and NFE2-like bZIP transcription factor 2 (NFE2L2, previously known as NRF2) (59), which hopefully will provide benefit for RP patients. The gene discussed is NFE2L2; the disease is respiratory distress syndrome in premature infants.